Research Progress in Applying Proteomics Technology to Explore Early Diagnosis Biomarkers of Breast Cancer, Lung Cancer and Ovarian Cancer

Luo, Liting; Dong, Li-You; Yan, Qi-Gui; Cao, San-Jie; Wen, Xin-Tian; Huang, Yong; Huang, Xiaobo; Ma, Xiaoping

doi:10.7314/apjcp.2014.15.20.8529

Cited by 26 publications

(17 citation statements)

References 100 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer is the major cause of cancer mortality worldwide with an approximation of 80% non-small cell lung cancer (NSCLC) [ 1 - 3 ]. Although tremendous improvements have been made in diagnosis and treatment, poor prognosis still exists in a large number of NSCLC patients with a low 5-year overall survival rate and a high recurrence rate [ 4 - 6 ]. Thus, it is utterly important to discover reliable biomarkers of profound prognostic value in NSCLC patients [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance

Zhang

et al. 2015

Eur J Med Res

View full text Add to dashboard Cite

BackgroundDespite present studies which suggested miR-133a as a promising biomarker for several cancers, there still exist no articles concerning the validated clinical significance of miR-133a in non-small cell lung cancer (NSCLC). Therefore, in this study, we targeted the correlation between miR-133a expression and clinicopathological significance in NSCLC patients.MethodsThe expression of miR-133a in 125 cases of NSCLC and their paired adjacent non-cancerous tissues was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Meanwhile, the relationship between miR-133a expression and several clinicopathological parameters and patient survival was analyzed.ResultsThe relative level of miR-133a was 2.0108 ± 1.3334 in NSCLC tissues, significantly lower than that of the adjacent non-cancerous lung tissues (3.6430 ± 2.2625, P = 0.019). The area under curve (AUC) of low expression of miR-133a to diagnose NSCLC was 0.760 (95% CI: 0.702 ~ 0.819, P < 0.001). MiR-133a expression was negatively correlated to lymphatic metastasis (r = −0.182, P = 0.042), tumor size (r = −0.253, P = 0.04), clinical TNM stages (r = −0.154, P = 0.087), and EGFR protein expression (r = −0.612, P < 0.001).ConclusionsMiR-133a serves as a tumor-suppressive miRNA in human NSCLC, and its downregulation suggests deterioration in NSCLC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance

Zhang

et al. 2015

Eur J Med Res

View full text Add to dashboard Cite

show abstract

“…Despite chemotherapy, radiotherapy, surgery, and target therapy has previously been developed in ovarian cancers [2], the 5-year overall survival rate for patients who diagnosed with late stage III−IV disease is still very poor (about 30%). Because of the site of the ovaries and the certain clinical characteristics of epithelial cancers, it is a challenge to make early diagnosis [3]. Women with high-risk factors (e.g., family history, or BRCA mutations) plan for a follow-up visit with cancer antigen 125 (CA-125) monitoring and ultrasound, however, prospective validation of these physical examination or lab tests remain elusive [4].…”

Section: Introductionmentioning

confidence: 99%

Energy Metabolism Heterogeneity-Based Molecular Biomarkers for Ovarian Cancer

Li¹,

Zhan²,

Zhan³

2019

Molecular Medicine

View full text Add to dashboard Cite

Energy metabolism heterogeneity is a hallmark in ovarian cancer; namely, the Warburg and reverse Warburg effects coexist in ovarian cancer. Exploration of energy metabolism heterogeneity benefits the discovery of the effective biomarkers for ovarian cancers. The integrative analysis of transcriptomics (20,115 genes in 419 ovarian cancer samples), proteomics (205 differentially expressed proteins), and mitochondrial proteomics (1198 mitochondrial differentially expressed proteins) revealed (i) the upregulations of rate-limiting enzymes PKM2 in glycolysis, IDH2 in Krebs cycle, and UQCRH in oxidative phosphorylation (OXPHOS) pathways, (ii) the upregulation of PDHB that converts pyruvate from glycolysis into acetyl-CoA in Krebs cycle, and (iii) that miRNA (hsa-miR-186-5p) and RNA-binding protein (EIF4AIII) had target sites in those key proteins in energy metabolism pathways. Furthermore, lncRNA SNHG3 interacted with miRNA (hsa-miR-186-5p) and RNA-binding protein (EIF4AIII). Those results were confirmed in the ovarian cancer cell model and tissues. It clearly concluded that lncRNA SNHG3 regulates energy metabolism through miRNA (hsa-miR-186-5p) and RNA-binding protein (EIF4AIII) to regulate the key proteins in the energy metabolism pathways. SNHG3 inhibitor might interfere with the energy metabolism to treat ovarian cancers. These findings provide more accurate understanding of molecular mechanisms of ovarian cancers and discovery of effective energy-metabolism-heterogeneity therapeutic drug for ovarian cancers. Highlights • Mitochondrial proteomics revealed the energy metabolism heterogeneity in ovarian cancers. • LncRNA SNHG3 was related to ovarian cancer survival and energy metabolism with ovarian cancer TCGA analysis. • SNHG3 was related to energy metabolism by regulating miRNAs and EIF4AIII based on GSEA and Starbase analyses. • MiRNAs and EIF4AIII regulate the glycolysis, Krebs cycle, and OXPHOS pathways by targeting PKM, PDHB, IDH2, and UQCRH.

show abstract

“…For the serological diagnosis in cancer thus far, classical blood-based tumor markers like carcinoembryonic antigen (CEA), prostate specific antigen (PSA), and carbohydrate antigen (CA) have gained a lot of recognition in the diagnosis or prediction of variety malignant tumors. Nevertheless, the utility of these available tumor markers is limited by disappointing diagnostic accuracies, especially with respect to their applications in diagnosing early phase carcinomas or incapability in distinguishing aggressive tumors from the indolent ones [ 1 , 2 ]. For instance, the accuracies of conventional CA15-3 and CEA revealed high volatilities for breast cancer detection, in which the discrepancy may due to ethnic group, sample size, or cancer subtype [ 3 , 4 ]; even for PSA, which is widely used in routine clinical practice for the screening and management of prostate cancer patients, the accuracy is not satisfactory as well [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-155 Hallmarks Promising Accuracy for the Diagnosis of Various Carcinomas: Results from a Meta-Analysis

Liu

2015

Disease Markers

View full text Add to dashboard Cite

Background. Recent studies have shown that microRNAs (miRNAs) have diagnostic values in various cancers. This meta-analysis seeks to summarize the global diagnostic role of miR-155 in patients with a variety of carcinomas. Methods. Eligible studies were retrieved by searching the online databases, and the bivariate meta-analysis model was employed to generate the summary receiver operator characteristic (SROC) curve. Results. A total of 17 studies dealing with various carcinomas were finally included. The results showed that single miR-155 testing allowed for the discrimination between cancer patients and healthy donors with a sensitivity of 0.82 (95% CI: 0.73–0.88) and specificity of 0.77 (95% CI: 0.70–0.83), corresponding to an area under curve (AUC) of 0.85, while a panel comprising expressions of miR-155 yielded a sensitivity of 0.76 (95% CI: 0.68–0.82) and specificity of 0.82 (95% CI: 0.77–0.86) in diagnosing cancers. The subgroup analysis displayed that serum miR-155 test harvested higher accuracy than plasma-based assay (the AUC, sensitivity, and specificity were, resp., 0.87 versus 0.73, 0.78 versus 0.74, and 0.77 versus 0.70). Conclusions. Our data suggest that single miR-155 profiling has a potential to be used as a screening test for various carcinomas, and parallel testing of miR-155 confers an improved specificity compared to single miR-155 analysis.

show abstract

Research Progress in Applying Proteomics Technology to Explore Early Diagnosis Biomarkers of Breast Cancer, Lung Cancer and Ovarian Cancer

Cited by 26 publications

References 100 publications

MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance

MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance

Energy Metabolism Heterogeneity-Based Molecular Biomarkers for Ovarian Cancer

MicroRNA-155 Hallmarks Promising Accuracy for the Diagnosis of Various Carcinomas: Results from a Meta-Analysis

Contact Info

Product

Resources

About